《MedRxiv,3月20日,Estimating Spot Prevalence of COVID-19 from Daily Death Data in Italy》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-03-22
  • Estimating Spot Prevalence of COVID-19 from Daily Death Data in Italy

    Ali Raheem

    doi: https://doi.org/10.1101/2020.03.17.20037697

    Abstract

    COVID-19 like many infectious diseases has a variable severity. Due to limited testing capacity for new virus, the majority of infected showing mild or no symptoms it is likely current prevalence data is an underestimate. We present an estimate of the point prevalence of COVID-19 compared to the number of confirmed case in Italy based on the daily death rate and information about the incubation period, time from symptom onset to death and reported case fatality rate. Our model predicts that when the first 3 infected cases had been identified by Italian authorities there were already nearly 30 cases in Italy, and by the 24th of February 2020 only 0.5% cases had been detected and confirmed by Italian authorities. While official statistics had 132 confirmed case we believe a more accurate estimate would be closer to 26000. With a case-doubling period of about 2.5 days.

    *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.

  • 原文来源:https://www.medrxiv.org/content/10.1101/2020.03.17.20037697v1
相关报告
  • 《MedRxiv,3月20日,Estimating the Risks from COVID-19 Infection in Adult Chemotherapy Patients》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-22
    • Estimating the Risks from COVID-19 Infection in Adult Chemotherapy Patients Matt Williams, Kerlann Le Calvez, Ella Mi, Jiarong Chen, Seema Dadhania, Lillie Pakzad-Shahabi doi: https://doi.org/10.1101/2020.03.18.20038067 Abstract The SARS-CoV-2 (COVID-19) novel coronavirus represents a significant health risk, particularly in older patients. Cancer is one of the leading causes of death in most rich countries, and delivering chemotherapy may be associated with increased risk in the presence of a pandemic infection. Estimating this risk is crucial in making decisions about balancing risks and benefits from administering chemotherapy. However, there are no specific data about chemotherapy risks per se. Here we develop a simple model to estimate the potential harms in patients undergoing chemotherapy during a COVID outbreak. *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.
  • 《MedRxiv,3月8日,Estimating the generation interval for COVID-19 based on symptom onset data》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-09
    • Estimating the generation interval for COVID-19 based on symptom onset data Tapiwa Ganyani, Cecile Kremer, Dongxuan Chen, Andrea Torneri, Christel Faes, Jacco Wallinga, Niel Hens doi: https://doi.org/10.1101/2020.03.05.20031815 Abstract Background: Estimating key infectious disease parameters from the COVID-19 outbreak is quintessential for modelling studies and guiding intervention strategies. Whereas different estimates for the incubation period distribution and the serial interval distribution have been reported, estimates of the generation interval for COVID-19 have not been provided. Methods: We used outbreak data from clusters in Singapore and Tianjin, China to estimate the generation interval from symptom onset data while acknowledging uncertainty about the incubation period distribution and the underlying transmission network. *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.